Octreotide as first-line treatment for women with metastatic breast cancer

被引：0
|
作者：
Ingle, JN
Kardinal, CG
Suman, VJ
Krook, JE
Hatfield, AK
机构：
[1] OCHSNER COMMUNITY CLIN ONCOL PROGRAM,NEW ORLEANS,LA 70121
[2] DULUTH COMMUNITY CLIN ONCOL PROGRAM,DULUTH,MN 55805
[3] COMMUNITY CLIN ONCOL PROGRAM,CARLE CANC CTR,URBANA,IL 61801
来源：
INVESTIGATIONAL NEW DRUGS | 1996年 / 14卷 / 02期
关键词：
octreotide; metastatic breast cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 mu g subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.
引用
收藏
页码：235 / 237
页数：3
相关论文
共 50 条
  • [1] First-line treatment of metastatic breast cancer
    Trudeau, ME
    ANTI-CANCER DRUGS, 1996, 7 : 9 - 12
  • [2] Bevacizumab in first-line treatment of metastatic breast cancer
    Miles, David
    DRUGS, 2007, 67 (12) : 1800 - 1800
  • [3] BevacizumabIn First-Line Treatment of Metastatic Breast Cancer
    Lesley J. Scott
    Drugs, 2007, 67 : 1793 - 1799
  • [4] Bevacizumab in the first-line treatment of metastatic breast cancer
    Cameron, David
    EJC SUPPLEMENTS, 2008, 6 (06): : 21 - 28
  • [5] First-line treatment with epirubicin and vinorelbine in metastatic breast cancer
    Vici, P
    Colucci, G
    Gebbia, V
    Amodio, A
    Giotta, F
    Belli, F
    Conti, F
    Gebbia, N
    Pezzella, G
    Valerio, MR
    Brandi, M
    Pisconti, S
    Durini, E
    Giannarelli, D
    Lopez, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2689 - 2694
  • [6] First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab
    Fujii, Teruhiko
    Takahashi, Hiroki
    Matsubayashi, Roka Namoto
    Inoue, Yuka
    Takenaka, Miki
    Toh, Uhi
    Kage, Masayoshi
    Yamana, Hideaki
    Shirouzu, Kazuo
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 583 - 593
  • [7] Taxanes as a First-Line Systemic Treatment in Metastatic Breast Cancer
    Urquhart, Laura M.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2013, 17 (01) : 15 - 21
  • [8] Use of bevacizumab as a first-line treatment for metastatic breast cancer
    Manso, L.
    Moreno, F.
    Marquez, R.
    Castelo, B.
    Arcediano, A.
    Arroyo, M.
    Ballesteros, A. I.
    Calvo, I.
    Echarri, M. J.
    Enrech, S.
    Gomez, A.
    Gonzalez del Val, R.
    Lopez-Miranda, E.
    Martin-Angulo, M.
    Martinez-Janez, N.
    Olier, C.
    Zamora, P.
    CURRENT ONCOLOGY, 2015, 22 (02) : E51 - E60
  • [9] First-Line Chemotherapy for Metastatic Breast Cancer
    Telli, Melinda L.
    Carlson, Robert W.
    CLINICAL BREAST CANCER, 2009, 9 : S66 - S72
  • [10] Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer
    Baltali, E
    Altundag, MK
    Güler, N
    Özisik, Y
    Firat, D
    Baran, I
    Tekuzman, G
    TUMORI, 2002, 88 (03) : 200 - 203
12345